This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D56.0 | Synonyms: α-thalassemia, Alpha-thalassaemia, HbH disease, Hb Bart's hydrops fetalis, Hemoglobin H disease
The concept of thalassemia began in 1925, when Thomas B. Cooley and P. Lee first described a syndrome of splenomegaly and severe anemia in children of Italian descent. In 1936, Whipple and Bradford described the pathological features of the disease more clearly, and the name thalassemia, combining the Greek words for 'sea' (thalassa) and 'blood' (haima), came into use. Initially, beta thalassemia and alpha thalassemia were not distinguished, and the molecular difference between the two types was clearly established only after the 1950s–1960s, when hemoglobin research advanced.
In the 1950s, Ingram and Stretton demonstrated that the alpha and beta chains of hemoglobin are synthesized by separate genes. In the 1970s, researchers including Kan, Dozy, and Orkin confirmed that alpha-globin gene deletions are the main cause of alpha thalassemia in Southeast Asian and Mediterranean populations. In particular, in 1974 Kan et al. clearly established the relationship between hydrops fetalis and Hb Bart's and demonstrated that it is caused by deletion of all four alpha-globin genes. Subsequently, advances in molecular cloning techniques allowed the structure and deletion types of the HBA1 and HBA2 genes to be characterized in detail.
Hemoglobin H (HbH) was first described in 1955 by Rigas, Koler, and Osgood. They found that an unusual hemoglobin fraction consisted of β4 tetramers, and it was later shown that this results from excess beta chains forming tetramers on their own when alpha-chain synthesis is severely reduced. Hb Bart's (γ4 tetramer) is a tetramer formed by excess gamma chains produced in fetal life; it appears as the predominant hemoglobin in fetuses with deletion of all four alpha genes and has extremely high oxygen affinity. In Korea, alpha thalassemia cases began to be gradually recognized after the 1990s with the increase in Southeast Asian immigrants and mixed-ethnicity families.
The most common cause of alpha thalassemia is partial or complete deletion of the HBA1 and HBA2 genes. On chromosome 16p13.3, two functional alpha-globin genes (HBA2 and HBA1, in the 5'→3' direction) are arranged about 4 kb apart. Deletions of these genes occur mainly through unequal crossover between highly repetitive sequences within this region. The most common deletion types are the Southeast Asian type (--SEA, deleting both HBA2 and HBA1), the Mediterranean types (-α3.7, -α4.2), the Filipino type (--FIL), and the Thai type (--THAI).
In addition to deletions, non-deletional mutations such as point mutations, splicing variants, and termination codon variants can cause alpha thalassemia. Non-deletional variants account for about 5–10% of all causes of alpha thalassemia and are found frequently, mainly in Southeast Asia. Non-deletional variants completely or partially abolish the function of the affected alpha-globin gene. Some non-deletional variants combine with structural hemoglobin abnormalities (e.g., Hb Constant Spring, Hb Icaria) in HbH disease, resulting in a particularly severe clinical picture.
Normally, humans have two alpha-globin genes (HBA2, HBA1) on each chromosome 16, for a total of four functional alpha-globin genes. The phenotypic spectrum according to the number of deleted genes is classified as follows.
| Number of deletions | Genotype notation | Clinical type | Key features |
|---|---|---|---|
| 1 deletion | -α/αα | Silent carrier (asymptomatic carrier) | Asymptomatic, normal blood picture |
| 2 deletions | --/αα or -α/-α | α-Thalassemia trait | Mild microcytosis, decreased MCH/MCV |
| 3 deletions | --/-α | HbH disease (hemoglobin H disease) | Moderate hemolytic anemia, HbH tetramer formation |
| 4 deletions | --/-- | Hb Bart's hydrops fetalis | Intrauterine hydrops, perinatal death, cannot survive without transfusion |
Cis deletions, in which the two deletions lie on the same chromosome (--/αα, Southeast Asian and Mediterranean types), and trans deletions, distributed across different chromosomes (-α/-α, African type), carry very different risks for subsequent children. Between parents heterozygous for cis deletions, the risk of giving birth to a baby with Hb Bart's hydrops fetalis is high, whereas between parents heterozygous for trans deletions, theoretically only up to HbH disease can occur. This ethnic specificity of deletion types has important implications for prenatal genetic testing strategies.
Alpha thalassemia is one of the most common single-gene disorders in the world, and about 5–30% of the world's population is estimated to carry some form of alpha-globin gene deletion. Carrier frequencies are especially high in populations of Southeast Asia, the Mediterranean coast, the Middle East, Africa, and the Indian subcontinent, which is understood to reflect the contribution of a natural selective advantage against falciparum malaria (Plasmodium falciparum) to maintaining carrier frequency. The prevalence of HbH disease is estimated at about 1/10,000–1/30,000, but varies greatly by region.
Alpha-globin gene deletions are relatively rare in Koreans, but owing to the increase in multicultural families and Southeast Asian immigrants, clinically significant cases of alpha thalassemia, including HbH disease and Hb Bart's hydrops, are increasing. Deletion types that are especially frequent in Koreans have not yet been systematically investigated, but East Asian-type deletions (--SEA, -α3.7) are mainly reported. With stronger diagnostic infrastructure and improved access to prenatal testing, early diagnoses in Korea are increasing.
In Southeast Asians, the --SEA deletion is the most common, so the risk of Hb Bart's hydrops fetalis is high. In Mediterranean populations, --MED (Mediterranean-type two-gene deletion) and single-gene deletions (-α3.7, -α4.2) are mixed. In populations of African descent, single deletions (-α3.7) predominate, so the frequency of the trans arrangement is high. In South Asian populations in the US, the frequency of non-deletional variants is relatively high.
Normal hemoglobins (HbA: α2β2, HbA2: α2δ2, HbF: α2γ2) all share the alpha chain. When alpha-chain synthesis decreases because of alpha-globin gene deletion, beta, gamma, and delta chains are produced in relative excess. Excess beta chains spontaneously form β4 tetramers (HbH) and gamma chains form γ4 tetramers (Hb Bart's). These abnormal tetramers are the key cause of hemolytic anemia.
In HbH (β4), heme iron is easily oxidized to form methemoglobin, and HbH is unstable and forms Heinz bodies. Heinz bodies attach to the red cell membrane, inducing phagocytosis in the spleen and accelerating premature red cell destruction (hemolysis). In addition, HbH has a much higher oxygen affinity than normal HbA, so it cannot release oxygen efficiently in tissues, worsening functional anemia.
Hb Bart's (γ4) has extremely high oxygen affinity (p50 ~1 mmHg) and delivers almost no oxygen to tissues. In fetuses with deletion of all four alpha genes, functional oxygen-carrying capacity is virtually lost, resulting in severe intrauterine tissue hypoxia. This causes heart failure, generalized edema (hydrops), hepatosplenomegaly, and placental edema, and the fetus dies in utero or shortly after birth. Serious complications such as preeclampsia and maternal liver cirrhosis can also occur in the pregnant woman.
The clinical symptoms of alpha thalassemia differ dramatically depending on the number of deleted alpha-globin genes. One deletion (silent carrier) is completely asymptomatic with normal blood findings. Two deletions (α-thal trait) show mild microcytic hypochromic anemia but are mostly asymptomatic, and differentiation from iron-deficiency anemia is important. Three deletions (HbH disease) cause moderate hemolytic anemia with pallor, jaundice, fatigue, and splenomegaly, and acute hemolytic crises can occur with infection, oxidant drugs, or fever. Patients survive into adulthood, but transfusion dependence varies. Four deletions (Hb Bart's hydrops fetalis) typically result in intrauterine death or death shortly after birth.
The most common symptoms in patients with HbH disease are jaundice, pallor, and splenomegaly. Cholelithiasis (pigment stones) can develop early, and anemia may worsen due to folate deficiency. Some patients with severe forms (especially with the non-deletional variant Hb Constant Spring) develop severe anemia, transfusion dependence, skeletal deformities due to bone marrow hyperplasia, and hepatomegaly. In adulthood, endocrine disorders (diabetes, hypothyroidism) may occur, and in chronically transfused patients iron overload is a major complication.
In HbH disease, the main signs on physical examination are pallor, jaundice (including scleral icterus), and splenomegaly. The degree of splenomegaly varies with disease severity and age. In severe HbH disease (with non-deletional variants), hepatosplenomegaly, growth failure, and skeletal deformities may be observed. Infants born with Hb Bart's hydrops fetalis are characterized by generalized edema, ascites, placental edema, and extreme pallor.
The complete blood count (CBC) is characterized by a marked decrease in MCH and MCV (MCH <25 pg, MCV <75 fL), and the Hb level is normal to mildly decreased in α-thal trait and in the range of 7–10 g/dL in HbH disease. The peripheral blood smear shows microcytosis, hypochromia, target cells, and, in HbH disease, Heinz bodies (identified by brilliant cresyl blue staining). Hemoglobin electrophoresis (Hb electrophoresis) identifies HbH and Hb Bart's fractions. Elevated indirect bilirubin, elevated LDH, and decreased haptoglobin appear as indicators of hemolysis.
Abdominal ultrasound commonly reveals splenomegaly and gallstones. In severe HbH, bone marrow MRI may show extensive hyperplastic marrow. In chronically transfused patients, liver MRI T2* imaging is used to assess the degree of iron overload.
Screening for alpha thalassemia is performed mainly in the context of prenatal screening. In pregnant women from high-risk regions (Southeast Asia, the Mediterranean, the Middle East) or with high-risk ethnic backgrounds, the MCV (<80 fL) and MCH (<27 pg) of the complete blood count (CBC) are used for screening. Serum ferritin or serum iron/TIBC is checked as well to exclude iron-deficiency anemia. If there is microcytosis and hypochromia without iron deficiency, hemoglobin electrophoresis or alpha-globin gene analysis is performed as additional testing.
If a two-deletion type (α-thal trait, --/αα or -α/-α) is identified in a pregnant woman, it is essential to perform screening of the partner as well. In particular, when both partners have the cis two-gene deletion (--/αα), there is a risk of Hb Bart's hydrops fetalis (25%), so prenatal genetic testing is strongly recommended.
In some Southeast Asian countries (Thailand, Singapore), alpha thalassemia is screened by detecting Hb Bart's in newborn blood tests. In Korea, it is not included in the standard newborn screening panel, but prenatal screening of high-risk mothers and the infrastructure for detailed genetic testing are gradually being strengthened.
The standard methods for hemoglobin analysis are high-performance liquid chromatography (HPLC) and capillary electrophoresis. They detect HbH (β4) and Hb Bart's (γ4) fractions, and in HbH disease an HbH fraction in the range of 1–40% is detected on HPLC. In α-thal trait (two deletions), no specific abnormal hemoglobin fraction is detected, so diagnosis by electrophoresis alone is difficult and molecular genetic testing is essential.
Gap-PCR is the standard method for detecting common deletion types (--SEA, -α3.7, -α4.2, --MED, etc.). If no deletion is detected by gap-PCR but alpha thalassemia is clinically suspected, atypical deletions are detected by MLPA (Multiple Ligation-dependent Probe Amplification), or point mutations are identified by sequencing of the HBA1 and HBA2 genes. Next-generation sequencing (NGS)-based hemoglobin disorder panels are also increasingly used.
In high-risk couples (both with cis two-gene deletions, or each with one deletion), alpha-globin gene analysis is performed on fetal DNA obtained by chorionic villus sampling (CVS, at 10–13 weeks of gestation) or amniocentesis (at 15–20 weeks of gestation) to make a prenatal diagnosis of Hb Bart's hydrops fetalis and HbH disease.
Most patients with HbH disease are managed with occasional transfusions alone. Folic acid supplementation (1–5 mg per day) is recommended to compensate for folate depletion due to chronic hemolysis. Drugs that induce Heinz body formation or increase oxidative stress (sulfonamides, some antimalarials) should be avoided. During acute hemolytic crises (with infection, fever, or use of oxidant drugs), packed red blood cell transfusion and supportive care are needed. If cholelithiasis develops, laparoscopic cholecystectomy is performed.
Patients with severe HbH disease combined with non-deletional variants (e.g., Hb Constant Spring) may require regular transfusion therapy. Because iron overload inevitably develops with chronic regular transfusion, iron chelation therapy (deferoxamine, deferasirox, deferiprone) must be given concurrently. Splenectomy may be considered to reduce transfusion requirements, but thorough management of the increased risk of thrombosis and susceptibility to infection is needed.
Hb Bart's hydrops fetalis leads to intrauterine death when it cannot be prevented. Some centers attempt treatment by keeping the fetus alive through intrauterine transfusion (IUT), followed by regular transfusions after birth and subsequent hematopoietic stem cell transplantation (HSCT). Successful HSCT has been reported in children who survived through IUT, but this treatment is limited to selected patients at specialized centers. Termination of pregnancy after prenatal diagnosis is also an option that can be chosen after ethical counseling.
Research on gene therapy for alpha thalassemia is currently progressing somewhat more slowly than for beta thalassemia. However, studies of CRISPR/Cas9-based gene correction and alpha-globin gene complementation using lentiviral vectors are under way at the preclinical stage, and their potential for future clinical application is being discussed.
Silent carriers and α-thal trait have no or very mild clinical symptoms, and the prognosis is good. They maintain normal life expectancy and quality of life and require no special treatment. The prognosis of HbH disease varies by form. Deletional HbH disease (three deletions) generally follows a relatively stable course into adulthood with reasonable management, and in many cases life expectancy is not greatly affected. However, non-deletional HbH disease (with Hb Constant Spring) shows more severe anemia and complications, and the prognosis may be poor. In Hb Bart's hydrops fetalis, intrauterine or perinatal death is inevitable unless IUT and HSCT are performed.
In patients with HbH disease, the key to long-term prognosis is management of iron overload, splenomegaly, and infection. In chronically transfused patients, cardiac siderosis, liver fibrosis, and endocrine complications can be major causes of death. In patients who undergo hematopoietic stem cell transplantation, long-term cure is possible if the transplant succeeds.
The key to preventing alpha thalassemia is carrier screening and genetic counseling in high-risk populations. When couples of Southeast Asian, Mediterranean, or Middle Eastern background plan a pregnancy, CBC-based screening and confirmatory molecular genetic testing are recommended. When both partners are carriers of the cis two-gene deletion, they should receive thorough counseling about the risk of Hb Bart's hydrops fetalis.
In high-risk couples, the fetal genotype is determined by prenatal genetic testing (CVS or amniocentesis) in each pregnancy. With in vitro fertilization, preimplantation genetic testing (PGT-M) can prevent implantation of affected embryos. Medical and ethical counseling should precede these choices.
To prevent complications in patients with HbH disease, the following are recommended: ① avoidance of drugs that induce oxidative stress, ② early treatment of infections, ③ regular hematologic follow-up, ④ folic acid supplementation, ⑤ vaccination if splenectomy is performed, and ⑥ regular monitoring for iron overload.